{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:50:24Z","timestamp":1772121024300,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.jhep.2014.06.005","type":"journal-article","created":{"date-parts":[[2014,6,16]],"date-time":"2014-06-16T16:38:33Z","timestamp":1402936713000},"page":"976-983","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Sustained virological response with telaprevir in 1078 patients with advanced hepatitis C: The international telaprevir access program"],"prefix":"10.1016","volume":"61","author":[{"given":"Massimo","family":"Colombo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Strasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo","family":"Abrao Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"Urbanek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Djamal","family":"Abdurakmonov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Streinu-Cercel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anke","family":"Verheyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wafae","family":"Iraqi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"DeMasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Lonjon-Domanec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2014.06.005_b0005","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"Mohd Hanafiah","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.06.005_b0010","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2014.06.005_b0015","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2009.09.067","article-title":"Aging of Hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression","volume":"138","author":"Davis","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.06.005_b0020","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1053\/gast.2002.34785","article-title":"Interferon therapy prolonged life expectancy among chronic hepatitis C patients","volume":"123","author":"Yoshida","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.06.005_b0025","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/hep.21492","article-title":"Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study","volume":"45","author":"Bruno","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.06.005_b0030","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2014.06.005_b0035","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(10)60934-8","article-title":"Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alpha-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial","volume":"376","author":"Kwo","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2014.06.005_b0040","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.06.005_b0045","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.06.005_b0050","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"Hezode","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.06.005_b0055","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.06.005_b0060","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.06.005_b0065","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/cid\/cir076","article-title":"Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more","volume":"52","author":"Pearlman","year":"2011","journal-title":"CID"},{"key":"10.1016\/j.jhep.2014.06.005_b0070","doi-asserted-by":"crossref","first-page":"399","DOI":"10.7326\/0003-4819-149-6-200809160-00006","article-title":"Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C","volume":"149","author":"Mallet","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2014.06.005_b0075","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.25606","article-title":"A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis","volume":"56","author":"D\u2019Ambrosio","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.06.005_b0080","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jhep.2009.12.028","article-title":"Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis","volume":"52","author":"Cardoso","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.06.005_b0085","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.amjmed.2007.06.022","article-title":"Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C","volume":"120","author":"Kawamura","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.jhep.2014.06.005_b0090","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/hep.26892","article-title":"Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients","volume":"59","author":"Hsu","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.06.005_b0095","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/hep.26087","article-title":"Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C","volume":"57","author":"Arase","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.06.005_b0100","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.cgh.2011.03.004","article-title":"A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C","volume":"9","author":"Backus","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2014.06.005_b0105","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jhep.2013.04.035","article-title":"Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)","volume":"59","author":"Hezode","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.06.005_b0110","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S0168-8278(13)60067-7","article-title":"Safety of triple therapy with telaprevir or boceprevir in hepatitis c patients with advanced liver disease \u2013 Predictive factors for sepsis","volume":"58","author":"Rutter","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.06.005_b0200","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2014.03.051","article-title":"Effectiveness of telaprevir or boceprevir in treatment experienced patients with HCV genotype 1 infection and cirrhosis","volume":"147","author":"Hezode","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.06.005_b0120","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/hep.25957","article-title":"Informed deferral: a moral requirement for entry into the hepatitis C virus treatment warehouse","volume":"56","author":"Aronsohn","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.06.005_b0125","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/gutjnl-2013-305667","article-title":"Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C","volume":"63","author":"Colombo","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2014.06.005_b0130","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","article-title":"Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C","volume":"128","author":"Cast\u00e9ra","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.06.005_b0135","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"Sherman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.06.005_b0140","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/apt.12494","article-title":"Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study","volume":"38","author":"Ogawa","year":"2013","journal-title":"Ailment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2014.06.005_b0145","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jhep.2013.11.003","article-title":"EASL clinical practice guidelines: management of hepatitis C virus infection","volume":"60","author":"European Association for Study of Liver","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.06.005_b0150","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","article-title":"Peginterferon alpha-2b or alpha-2a with ribavirin for treatment of hepatitis C infection","volume":"361","author":"McHutchison","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.06.005_b0155","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1002\/hep.25892","article-title":"High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials","volume":"56","author":"Marcellin","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.06.005_b0160","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0149-2918(11)00022-1","article-title":"A review of the treatment of chronic hepatitis C virus infection in cirrhosis","volume":"32","author":"Vezali","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.jhep.2014.06.005_b0165","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/jmv.23824","article-title":"Alpha-fetoprotein is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with the IL28B minor genotype","volume":"86","author":"Shimada","year":"2014","journal-title":"J Med Virol"},{"key":"10.1016\/j.jhep.2014.06.005_b0170","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/apt.12546","article-title":"Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort","volume":"39","author":"Backus","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2014.06.005_b0175","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/hep.25962","article-title":"Characterisation of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial","volume":"56","author":"De Meyer","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.06.005_b0180","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1046\/j.1365-2893.2001.00291.x","article-title":"Hepatitis C virus genotypes: distribution and clinical significance in patients with cirrhosis type C seen at tertiary referral centres in Europe","volume":"8","author":"Fattovich","year":"2001","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2014.06.005_b0185","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1478-3231.2011.02720.x","article-title":"Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders","volume":"32","author":"Forestier","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2014.06.005_b0190","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1053\/j.gastro.2009.05.007","article-title":"Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial","volume":"137","author":"Everhart","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.06.005_b0195","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1053\/jhep.2003.50350","article-title":"High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C","volume":"38","author":"Bressler","year":"2003","journal-title":"Hepatology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827814004000?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827814004000?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T06:23:31Z","timestamp":1538547811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827814004000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0168827814004000"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2014.06.005","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718457183.793496586","asserted-by":"object"}]},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sustained virological response with telaprevir in 1078 patients with advanced hepatitis C: The international telaprevir access program","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2014.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}